{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Arrestier R"],"funding":["NCRR NIH HHS","NIAID NIH HHS"],"pagination":["121"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9803887"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["<h4>Background</h4>Auto-antibodies (auto-Abs) neutralizing type I interferons (IFN) have been found in about 15% of critical cases COVID-19 pneumonia and less than 1% of mild or asymptomatic cases. Determining whether auto-Abs influence presentation and outcome of critically ill COVID-19 patients could lead to specific therapeutic interventions. Our objectives were to compare the severity at admission and the mortality of patients hospitalized for critical COVID-19 in ICU with versus without auto-Abs.<h4>Results</h4>We conducted a prospective multicentre cohort study including patients admitted in 11 intensive care units (ICUs) from Great Paris area hospitals with proven SARS-CoV-2 infection and acute respiratory failure. 925 critically ill COVID-19 patients were included. Auto-Abs neutral"],"journal":["Annals of intensive care"],"pubmed_title":["Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study."],"pmcid":["PMC9803887"],"funding_grant_id":["R01 AI088364","R01 AI163029","UL1 RR024143"],"pubmed_authors":["Moncomble E","Ben Ahmed M","Parfait M","Bizien L","Gaudry S","Mekontso-Dessap A","Pham T","Gervais A","Fage N","Belmondo T","Dorgham K","de Prost N","Luyt CE","Azoulay E","Voiriot G","Bastard P","Roux D","Hue S","Arrestier R","Urbina T","Casanova JL","Clere-Jehl R","Ait-Oufella H","Ait-Hamou Z","Mayaux J","Canoui-Poitrine F","Gorochov G","Segaux L","Bellaiche R"],"additional_accession":[]},"is_claimable":false,"name":"Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study.","description":"<h4>Background</h4>Auto-antibodies (auto-Abs) neutralizing type I interferons (IFN) have been found in about 15% of critical cases COVID-19 pneumonia and less than 1% of mild or asymptomatic cases. Determining whether auto-Abs influence presentation and outcome of critically ill COVID-19 patients could lead to specific therapeutic interventions. Our objectives were to compare the severity at admission and the mortality of patients hospitalized for critical COVID-19 in ICU with versus without auto-Abs.<h4>Results</h4>We conducted a prospective multicentre cohort study including patients admitted in 11 intensive care units (ICUs) from Great Paris area hospitals with proven SARS-CoV-2 infection and acute respiratory failure. 925 critically ill COVID-19 patients were included. Auto-Abs neutral","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-07-14T16:59:02.331Z","creation":"2025-04-20T00:13:12.626Z"},"accession":"S-EPMC9803887","cross_references":{"pubmed":["36586050"],"doi":["10.1186/s13613-022-01095-5"]}}